دورية أكاديمية
Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study.
| العنوان: | Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study. |
|---|---|
| المؤلفون: | Duvivier, Herbert L, Rothe, Michael, Mangat, Pam K, Garrett-Mayer, Elizabeth, Ahn, Eugene R, Al Baghdadi, Tareq, Alva, Ajjai S, Dublis, Stephanie A, Cannon, Timothy L, Calfa, Carmen J, Li, Rui, Behl, Deepti, Chiu, Vi K, Gold, Philip J, Marr, Alissa S, Mileham, Kathryn F, Powell, Steven Francis, Rodon, Jordi, Thota, Ramya, Grantham, Gina N, Gregory, Abigail, Hinshaw, Dominique C, Halabi, Susan, Schilsky, Richard L |
| المصدر: | Articles, Abstracts, and Reports |
| بيانات النشر: | Providence St. Joseph Health Digital Commons |
| سنة النشر: | 2023 |
| المجموعة: | Providence St. Joseph Health Digital Commons |
| مصطلحات موضوعية: | washington, swedish cancer, portland, oregon, genomics, Oncology |
| الوصف: | PURPOSE: The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a pragmatic basket trial evaluating antitumor activity of approved targeted agents in patients with advanced cancers harboring potentially actionable genomic alterations. Data from cohorts of patients with high tumor mutational burden (HTMB, defined as ≥9 mutations per megabase) with advanced colorectal cancer (CRC) and other advanced cancers treated with pembrolizumab are reported. METHODS: Eligible patients were 18 years and older with measurable tumors and a lack of standard treatment options, an Eastern Cooperative Oncology Group performance status of 0-1, and adequate organ function. The primary end point was disease control (DC), defined as complete or partial response or stable disease (SD) of at least 16-weeks duration. For the CRC cohort, Simon's two-stage design with a null DC rate of 15% versus 35% (power = 0.85; α = .10) was used. Low accruing histology-specific cohorts were collapsed into one histology-pooled (HP) cohort. For the HP cohort, the null hypothesis of a DC rate of 15% was rejected if the lower limit of a one-sided 90% CI was >15%. Secondary end points included objective response (OR), safety, progression-free survival, overall survival, duration of response, and duration of SD. RESULTS: Seventy-seven patients with HTMB with CRC (n = 28) or advanced cancers (n = 49) were treated with pembrolizumab. For the CRC cohort, the DC rate was 31% ( CONCLUSION: Pembrolizumab demonstrated antitumor activity in pretreated patients with advanced cancers and HTMB. |
| نوع الوثيقة: | text |
| اللغة: | unknown |
| العلاقة: | https://digitalcommons.providence.org/publications/7832Test; https://pubmed.ncbi.nlm.nih.gov/37561967Test |
| الإتاحة: | https://digitalcommons.providence.org/publications/7832Test https://pubmed.ncbi.nlm.nih.gov/37561967Test |
| رقم الانضمام: | edsbas.BE5B49A2 |
| قاعدة البيانات: | BASE |
| الوصف غير متاح. |